



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): MAUL et al.

SERIAL NO.: 10/751,737

ART UNIT:

FILING DATE: 1/5/04

EXAMINER:

TITLE: USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS
PHARMACEUTICAL PREPARATIONS

ATTORNEY

DOCKET NO.: 785-011642-US (C01)

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §1.97(b)(3))

Sir:

This supplemental information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

"Nitric Oxide Synthase Inhibition In Migraine" (pp.401-402)

"Nitric Oxide: From Basic Research To Clinical Applications"
(pp.47-49)

"Nitric Oxide Theory Of Migraine" (pp.28-33)

"Inhibition Of Nitric Oxide Synthase As A Potential Therapeutic
Target" (pp. 191-220)

"Die Entdeckung Einiger Biologischer Wirkungen Von
Stickstoffmonoxid Und Seiner Rolle Für Die Zellkommunikation
(Nobel-Vortrag) (pp.1977-1989)


"Stickstoffmonoxid: Ein Einzigartiges Endogenes Signalmolekül In
Der Gefäßbiologie (Nobel-Vortrag) (pp.2003-2013)

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,



Geza C. Ziegler, Jr.

Reg. No. 44,004

19 MARCH 2004
Date

PERMAN & GREEN, LLP
425 Post Road
Fairfield, CT 068424
Customer No. 2512

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope address to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 3/19/04

Signature: Shannon Watt
Shannon Watt



**INFORMATION DISCLOSURE
CITATION FORM FOR
PATENT APPLICATION
(FORM PTO-1449)
(Substitute)**

Docket No.: 785-011642-US(C01)

Serial No.: 10/751,737

Applicant(s): MAUL et al.

Filing Date: 1/5/04

Group:

U.S. PATENTS

Initials	Patent Number	Issue Date	Name	Class	Sub-class	Filing date

U.S. PATENT PUBLICATIONS

Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date

FOREIGN PATENT DOCUMENTS

Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a

OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)

	Lassen et al., "Nitric Oxide Synthase Inhibition in Migraine", February 8, 1997, Gloucester Gastroenterology Group, Gloucester, UK, pages 401-402.
	Green et al., "Nitric Oxide: From Basic Research to Clinical Applications", February 2, 1999, DDT, vol. 4, Pages 47-49.
	Thomsen et al., "Nitric Oxide Theory of Migraine", 1998, Clinical Neuroscience, pages 28-33.
	Hobbs et al., "Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target", Annu. Rev. Pharmacol. Toxicol., 1999, pages 191-220.
	Murad, "Die Entdeckung Einiger Biologischer Wirkungen Von Stickstoffmonoxid Und Seiner Rolle Fur Die Zellkommunikation (Nobel-Vortrag), Angew. Chem., 1999, pages 1977-1989.
	Ignaro, "Stickstoffmonoxid: Ein Einzigartiges Endogenes Signalmolekül In Der Gefäßbiologie (Nobel-Vortrag)" Angew. Chem., 1999, pages 2003-2013.

Examiner's Signature:

Date Considered:

Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered.
Include a copy of this citation form with your next correspondence to the Applicant(s).

Customer No.: 2512